TRAX (First Tracks Biotherapeutics) EBITDA Margin %: 0.00% (As of Dec. 2024)


TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $36.24
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics EBITDA Margin %?

First Tracks Biotherapeutics TRAX +11.85% 12 EBITDA Margin % is 0.00% as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 939 Biotechnology companies, First Tracks Biotherapeutics ranks worse than 106496.17% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. First Tracks Biotherapeutics's EBITDA for the six months ended in Dec. 2024 was $-178.70 Mil. First Tracks Biotherapeutics's Revenue for the six months ended in Dec. 2024 was $0.00 Mil. Therefore, First Tracks Biotherapeutics's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.

First Tracks Biotherapeutics  (NAS:TRAX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

First Tracks Biotherapeutics EBITDA Margin % Related Terms

First Tracks Biotherapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics EBITDA Margin % Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
EBITDA Margin %
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
EBITDA Margin % 0.00 0.00

TRAX vs ALT, RGNX, MDXG: EBITDA Margin % Comparison

For the Biotechnology subindustry, First Tracks Biotherapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

First Tracks Biotherapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where First Tracks Biotherapeutics's EBITDA Margin % falls into.


TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

First Tracks Biotherapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-178.704/0
= %

First Tracks Biotherapeutics's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-178.704/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
First Tracks Biotherapeutics (TRAX) has a EBITDA Margin % of 0.00% as of Dec. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on First Tracks Biotherapeutics and its competitors. According to the industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 939 companies in the Biotechnology industry.
Is First Tracks Biotherapeutics' EBITDA Margin % too high?
First Tracks Biotherapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, First Tracks Biotherapeutics ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' EBITDA Margin % compare to ALT and RGNX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 939 companies for EBITDA Margin %. This places First Tracks Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current EBITDA Margin % is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.24
Price